Partnership supports radiopharmaceutical solid tumour development
Akiram Therapeutics has signed an agreement with ITM for the supply of non-carrier-added lutetium-177 (n.c.a. Lu-177) to support the ongoing clinical trial of AKIR001, its lead radiopharmaceutical candidate for the treatment of solid tumours. Lu-177 is one of the most widely used medical radioisotopes in targeted radionuclide therapy and serves… Read More